259 related articles for article (PubMed ID: 32801102)
1. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
3. Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate.
Velez FF; Bond TC; Anastassopoulos KP; Wang X; Sousa R; Blum D; Cramer JA
Epilepsy Behav; 2017 Mar; 68():203-207. PubMed ID: 28236698
[TBL] [Abstract][Full Text] [Related]
4. Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate.
Cramer JA; Velez FF; Anastassopoulos KP; Bond TC; Gilliam FG; Ryvlin P; Specchio LM; Wang X; Blum D; Moreira J; Rocha F
Epilepsy Behav; 2015 Dec; 53():149-53. PubMed ID: 26575256
[TBL] [Abstract][Full Text] [Related]
5. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
6. Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate.
Krishnaiengar SR; Cantu D; Hall D; Gama H; Pereira A; Grinnell T
Epilepsy Behav; 2023 Nov; 148():109466. PubMed ID: 37839247
[TBL] [Abstract][Full Text] [Related]
7. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
[TBL] [Abstract][Full Text] [Related]
10. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
[TBL] [Abstract][Full Text] [Related]
12. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials.
Cramer JA; Rajagopalan K; Anastassopoulos KP; Blum D;
Epilepsy Behav; 2019 Mar; 92():31-35. PubMed ID: 30611005
[TBL] [Abstract][Full Text] [Related]
14. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
[TBL] [Abstract][Full Text] [Related]
15. The ROME (Retrospective Observational Multicenter study on Eslicarbazepine) study: Efficacy and behavioural effects of Eslicarbazepine acetate as adjunctive therapy for adults with partial onset seizures in real life.
Assenza G; Mecarelli O; Lanzone J; Assenza F; Tombini M; Di Lazzaro V; Pulitano P
Seizure; 2018 May; 58():35-40. PubMed ID: 29649684
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures.
Hixson J; Gidal B; Pikalov A; Zhang Y; Mehta D; Blum D; Cantu D; Grinnell T;
Epilepsy Res; 2021 Mar; 171():106561. PubMed ID: 33556737
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis.
Brandt C; Borghs S; Elmoufti S; Mueller K; Townsend R; de la Loge C
Epilepsy Behav; 2017 Apr; 69():80-85. PubMed ID: 28236727
[TBL] [Abstract][Full Text] [Related]
19. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
[TBL] [Abstract][Full Text] [Related]
20. Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
Altalib H; Grinnell T; Cantu D; Ikedo F; Vieira M; Zhang Y; Blum D
Epilepsia Open; 2022 Dec; 7(4):616-632. PubMed ID: 35908275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
